|
1）Lee AY, Yates NA, Ichetovkin M, et al. Measure-ment of fractional synthetic rates of multiple protein analytes by triple quadrupole mass spectrometry. Clin. Chem. 2012; 58(3): 619-27
|
|
|
|
|
2）Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006; 12(7): 856-61
|
|
|
|
|
3）Ikewaki K, Rader DJ, Schaefer JR, et al. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res. 1993; 34: 2207-15
|
|
|
|
|
|
4）Ikewaki K, Zech LA, Brewer HB Jr, et al. ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. J Lipid Res. 1996; 37: 399-407
|
|
|
|
|
|
5）Ikewaki K, Rader DJ, Sakamoto T, et al. Delayed catabolism of high density lipoprotein apolipo-proteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest. 1993; 92(4): 1650-8
|
|
|
|
|
|
6）Ikewaki K, Nishiwaki M, Sakamoto T, et al. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest. 1995; 96: 1573-81
|
|
|
|
|
|
7）Rader DJ, Ikewaki K, Duverger N, et al. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest. 1994; 93(1): 321-30
|
|
|
|
|
|
8）Tada H, Kawashiri MA, Ikewaki K, et al. Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet. 2012; 5(1): 35-41
|
|
|
|
|
|
9）Okubo K, Ikewaki K, Sakai S, et al. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol. 2004; 15(4): 1008-15
|
|
|
|
|
|
10）Ikewaki K, Schaefer JR, Frischmann ME, et al. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol. 2005; 25(12): 2615-22
|
|
|
|
|
|
11）Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007; 356(2): 148-56
|
|
|
|
|
|
12）Adiels M, Boren J, Caslake MJ, et al. Overpro-duction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2005; 25(8): 1697-703
|
|
|
|
|
|
13）Cummings MH, Watts GF, Umpleby AM, et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia. 1995; 38(8): 959-67
|
|
|
|
|
|
14）Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003; 46(6): 733-49
|
|
|
|
|
|
15）Duvillard L, Pont F, Florentin E, et al. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis. 2000; 152(1): 229-37
|
|
|
|
|
|
16）Frenais R, Ouguerram K, Maugeais C, et al. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia. 1997; 40(5): 578-83
|
|
|
|
|
|
17）Duvillard L, Florentin E, Pont F, et al. Endogenous chronic hyperinsulinemia does not increase the production rate of VLDL apolipopro-tein B: proof from a kinetic study in patients with insulinoma. J Clin Endocrinol Metab. 2011; 96(7): 2163-70
|
|
|
|
|
|
18）Millar JS, Maugeais C, Ikewaki K, et al. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol. 2005; 25(3): 560-5
|
|
|
|
|